DelveInsight’s “Myocardial Infarction Market” report provides a thorough comprehension of the Myocardial Infarction historical and forecasted epidemiology and the Myocardial Infarction market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Myocardial Infarction market report also proffers an analysis of the current Myocardial Infarction treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
Some of the necessary takeaways from the Myocardial Infarction Market Research Report
Several key pharmaceutical companies, including Pfizer, Sanofi, Aventis, Bristol-Myers Squibb, AstraZeneca, Merck, Eli Lilly and Company, Daiichi Sankyo Co., Takeda, Novartis, Genentech, Amgen, Boehringer Ingelheim, Biocardia, Faraday Pharma, CSL Behring, Idorsia, and others, are developing novel products to improve the Myocardial Infarction treatment outlook.
In September 2020, the FDA granted Fast Track designation for the development of Jardiance (empagliflozin) to inhibit hospitalization for heart failure and decrease the risk of mortality in patients, with and without diabetes, who have had an Acute Myocardial Infarction.
In July 2020, AstraZeneca was granted Fast Track Designation in the US for the Farxiga (dapagliflozin) development to lessen the risk of hospitalization for heart failure (hHF) or cardiovascular (CV) death in adults following an Acute Myocardial Infarction (MI) or heart attack.
The widespread adoption of a commonly accepted definition for Myocardial Infarction and uniform use of cardiac troponin as the biomarker of choice may increase the ability of future studies on Myocardial Infarction epidemiology to make more valid inferences about improvements in health. In recent years, there have been technological advancements due to active research & development, leading to an expected entry of new therapies driving the growth of the Myocardial Infarction market.
In contrast to that, the Myocardial Infarction market might be impeded by the heterogeneity of patients, along with the duration of treatment and modalities, and the lack of emergency care awareness, making it challenging to evaluate the usefulness of a large chunk of pipeline drugs, particularly in Myocardial Infarction patients.
For further information on Market Impact by Therapies, visit: Myocardial Infarction Drugs Market Analysis
Myocardial Infarction, commonly known as a heart attack, occurs when blood flow reduces or stops to a part of the heart, causing damage to the heart muscle.
DelveInsight estimates that the total Myocardial Infarction prevalent cases in the 7MM were 13,123 cases in 2020. It was also observed that the prevalence of Myocardial Infarction is more common among males than females.
The Myocardial Infarction Market Analysis Report provides historical as well as forecasted epidemiological analysis segmented into:
Myocardial Infarction Prevalent Cases
Gender-specific cases of Myocardial Infarction
Type-specific cases of Myocardial Infarction
Get a complete epidemiological segmentation breakdown @ Myocardial Infarction Epidemiological Analysis
Myocardial Infarction Treatment Market
The current Myocardial Infarction market has been segmented into different commonly used therapeutic classes such as Antiplatelet agents, Anticoagulants, Vasodilators, Beta Blockers, Lipid-lowering drugs/Statins, ACE inhibitors, ARBs (Angiotensin-II receptor Blockers) and Calcium channel blockers are the significant classes. They are based on the prevailing treatment pattern across the 7 MM, which presents minor variations in the overall prescription pattern.
Eplerenone, sold under the brand name Inspra, is a steroidal antimineralocorticoid of the spironolactone group used as an adjunct in managing chronic heart failure and high blood pressure, particularly for patients with resistant hypertension due to elevated aldosterone. Eplerenone is an aldosterone antagonist or mineralocorticoid receptor antagonist (MRA), used mainly for its diuretic properties.
The sodium-glucose cotransporter 2 inhibitors (SGLT2i) empagliflozin, dapagliflozin has shown impressive beneficial effects in patients with type-2 diabetes mellitus in mandatory cardiovascular outcome trials.
Atherosclerotic coronary vascular disease is the major cause of death, so stem cell therapy is being investigated in patients with acute myocardial infarction (AMI) to limit myocardial damage and possibly regenerate the myocardium. The investigational CardiAMP therapy uses the patient’s bone marrow cells to potentially stimulate the body’s natural healing response through a minimally invasive, catheter-based procedure. BioCardia is a leader in the development of comprehensive solutions for cardiovascular regenerative therapies.
In recent years, it has been shown that pre-hospital thrombolysis has a role in managing patients seen early after symptom onset in comparison/association with patients who had primary coronary intervention or elective primary coronary intervention. This is an important issue currently being investigated to prevent cardiac arrest, significant scarring, limit the transition to heart failure, and improve the survival rate after acute myocardial infarction. Therefore, management of AMI has been regularly well defined over the last decades and recently updated by different Cardiac organizations to help physicians in routine clinical practice.
Myocardial Infarction Market Dynamics